SLXN

Silexion Therapeutics Corp

Feb 02 • 09:38AM ET

1.83

-0.00 -0.14 %

Healthcare • Biotechnology • Israel • NASD

Index	-	P/E	-	EPS (ttm)	-25.21	Insider Own	26.02%	Shs Outstand	3.13M	Perf Week	-8.85%
Market Cap	5.71M	Forward P/E	-	EPS next Y	-4.39	Insider Trans	0.00%	Shs Float	2.31M	Perf Month	-4.82%
Enterprise Value	-1.54M	PEG	-	EPS next Q	-1.12	Inst Own	1.17%	Short Float	2.10%	Perf Quarter	-44.62%
Income	-9.25M	P/S	-	EPS this Y	98.47%	Inst Trans	-9.29%	Short Ratio	0.84	Perf Half Y	-80.31%
Sales	0.00M	P/B	0.82	EPS next Y	27.17%	ROA	-125.80%	Short Interest	0.05M	Perf YTD	-4.82%
Book/sh	2.23	P/C	0.62	EPS next 5Y	77.73%	ROE	-771.23%	52W High	36.00 -94.92%	Perf Year	-94.06%
Cash/sh	2.97	P/FCF	-	EPS past 3/5Y	-286.21% -286.09%	ROIC	-104.75%	52W Low	1.65 10.79%	Perf 3Y	-99.86%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.68% 10.04%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	91.47%	Oper. Margin	-	ATR (14)	0.19	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.97	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	35.76	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.97	EPS Q/Q	98.95%	SMA20	-13.21%	Beta	-0.04	Target Price	9.00
Payout	-	Debt/Eq	0.29	Sales Q/Q	-	SMA50	-22.89%	Rel Volume	0.91	Prev Close	1.83
Employees	14	LT Debt/Eq	0.27	Earnings	Nov 12 BMO	SMA200	-75.08%	Avg Volume	57.86K	Price	1.83
IPO	Apr 07, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	15.29% -	Trades		Volume	4,038	Change	-0.14%

Jan-21-26 08:30AM	Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit (GlobeNewswire) -5.80%
Jan-06-26 07:30AM	Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026 (GlobeNewswire)
Dec-16-25 08:40AM	Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer (GlobeNewswire)
Dec-02-25 08:00AM	Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer (GlobeNewswire) -7.61%
Nov-26-25 07:30AM	Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference (GlobeNewswire) +20.42%
09:15AM	Loading…
Nov-25-25 09:15AM	Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer (GlobeNewswire) +7.62%
Nov-12-25 09:00AM	Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Sep-30-25 08:40AM	Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer (GlobeNewswire)
Sep-25-25 08:45AM	Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Sep-11-25 09:17AM	Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering (GlobeNewswire) +9.92%
07:00AM	Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration (GlobeNewswire)
Sep-04-25 09:25AM	Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204 (GlobeNewswire)
Sep-02-25 08:45AM	Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-12-25 08:00AM	Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 08:00PM	Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds (GlobeNewswire) +31.98% -37.88%
09:55AM	Loading…
09:55AM	Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation (GlobeNewswire)
Jul-16-25 08:44AM	Silexion Therapeutics Announces 1-for-15 Reverse Share Split (GlobeNewswire) -8.56%
Jul-09-25 08:30AM	Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines (GlobeNewswire) +12.33%
May-30-25 09:10AM	Silexion Therapeutics announces preclinical results on SIL204 (TipRanks) +8.33%
May-29-25 11:43PM	Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors (Insider Monkey)
09:05AM	Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers (GlobeNewswire)
May-21-25 08:45AM	Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer (GlobeNewswire)
May-13-25 04:45PM	Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-23-25 09:20AM	Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities (GlobeNewswire) +46.51%
Mar-28-25 08:30AM	Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data (GlobeNewswire)
Mar-21-25 08:30AM	Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference (GlobeNewswire)
Mar-18-25 04:29PM	Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.20%
Mar-17-25 08:15AM	PESG Report: Silexion Therapeutics Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis Signaling a Potential Paradigm Shift in Cancer Treatment (Business Wire)
Mar-05-25 08:30AM	Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models (GlobeNewswire) +30.63%
Mar-03-25 08:30AM	PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational (Business Wire)
08:30AM	Loading…
Feb-25-25 08:30AM	Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204 (GlobeNewswire) +64.00%
Jan-29-25 05:30PM	Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds (GlobeNewswire) +132.59% -34.71%
09:59AM	PESG Report: Silexion Therapeutics Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market (Business Wire)
Jan-28-25 08:29AM	Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models (GlobeNewswire) +132.76%
Jan-16-25 11:04AM	PESG Market Update: Silexion Therapeutics SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments (Business Wire) -39.74%
Jan-15-25 08:00PM	Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) -11.86%
04:01PM	Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies (GlobeNewswire)
Jan-13-25 07:50AM	Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Dec-18-24 06:35AM	Silexion Therapeutics, Evonik collaborate on siRNA formulation development (TipRanks) -26.21%
Dec-17-24 09:36AM	PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises (Business Wire) -10.77%
06:30AM	Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development (GlobeNewswire)
Dec-10-24 08:30AM	Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors (GlobeNewswire)
Nov-22-24 04:30PM	Silexion Therapeutics Announces 1-for-9 Reverse Share Split (GlobeNewswire)
Nov-20-24 08:30AM	Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference (GlobeNewswire) +47.26%
Nov-14-24 08:30AM	Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (ACCESSWIRE) -8.73%
Oct-09-24 05:35PM	Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit (ACCESSWIRE) -11.93% -5.98%
Oct-01-24 06:45AM	Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies (Business Wire) +5.90%
Sep-24-24 07:30AM	Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER in Non-Resectable Pancreatic Cancer (Business Wire) -16.28%
Sep-09-24 07:32AM	PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers (Business Wire) +11.61%
Sep-03-24 04:05PM	Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference (GlobeNewswire) -24.66% -10.98%
Aug-15-24 04:05PM	Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination (GlobeNewswire) -13.21% -79.39%

Silexion Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery and development of treatments for KRAS-driven cancers. The company was founded on November 30, 2008 and is headquartered in in Modiin, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLXN

Silexion Therapeutics Corp

Upgrade your FINVIZ experience